• nextmarkets

  Participated · Series B · Mar 2021

  nextmarkets is a commission-free online broker that provides a stock exchange to trade shares and ETFs via a proprietary technology platform. The platform hosts professional investors, called coaches, who generate up to 300 curated investment ideas for users every month. Founded in 2014 by CEO Manuel Heyden and CTO Dominic Heyden, the company operates offices in Cologne, Lisbon and Malta and employs a team of 39. By the end of 2020 it had launched in Germany and Austria plus six additional countries: the United Kingdom, Portugal, the Netherlands, France, Spain and Italy. nextmarkets intends to use recent funding to further develop the platform and accelerate European expansion. The core product blends trading infrastructure with curated investment ideas from professional coaches. nextmarkets operates a platform that helps private investors trade by offering real-time coaching from 14 investment professionals who analyze over 1,000 markets and deliver trading ideas on web and mobile. The company supports trading across stocks, indices, foreign exchange, commodities and plans to add ETFs and crypto currencies. Led by CEO Manuel Heyden and CTO Dominic Heyden, nextmarkets has offices in Cologne and Malta and recently obtained a banking license in Malta. Financially, the company has raised €12m to date and is continuing to scale its product and commercial footprint. The latest funding will be used to drive dynamic growth across Europe and globally. The product focus and regulatory positioning (banking license) support its expansion plans.

• TME Pharma

  Participated · Series D · Oct 2010

  TME Pharma is a clinical-stage biotechnology company focused on developing therapies that target the tumor microenvironment, with lead assets NOX-A12 and NOX-E36. NOX-A12 is being studied in the GLORIA Phase 1/2 trial in glioblastoma and is planned for the OPTIMUS Phase 2 program in pancreatic cancer; NOX-E36 is being evaluated for ophthalmic diseases. Under CEO Diede van den Ouden (joined June 2025) the company has implemented a strategic restructuring and shifted to an outsourcing model to lower operating costs. Financially, the company raised €1.7M in May 2025 and is now securing an additional €500,000 via a private bond issuance to improve runway. Proceeds are intended to support R&D, a newly announced treasury investment strategy, and potential acquisitions and partnerships. The company is also pursuing cash-generating non-core activities, leveraging tax loss carryforwards and has opened exposure to digital assets via a crypto brokerage account to build a more profitable corporate structure. TME Pharma (ALTME) is a biotech focused on NOX-A12, an agent being developed for brain cancer, including glioblastoma. The company will use new funding to advance the phase 1/2 GLORIA trial in newly diagnosed brain-cancer patients who cannot receive standard chemotherapy. Proceeds are also earmarked to finalize a formal advisory meeting with the FDA on next clinical and regulatory steps for NOX-A12. TME Pharma plans to file IND applications and requests for an accelerated regulatory pathway using the funds. The financing extends the company’s financial visibility from February 2024 to May 2024. The company is referenced with a Berlin location in the article. NOXXON Pharma is a Berlin-based biotechnology company developing a class of therapeutics called Spiegelmers, oligonucleotides composed of the L-stereoisomer of RNA. The company is advancing these Spiegelmer therapeutics as its core product area. In May 2010 it raised €33m as part of its Series D, and it has now completed an additional €2m, bringing the Series D aggregate to €35m. New investors in the most recent tranche include CD Ventures and other private partners. The Series D syndicate also comprises a range of existing investors that have participated in the round. NOXXON currently employs approximately 60 people. NOXXON Pharma is a Berlin, Germany-based company developing mirror-image oligonucleotide therapeutics generated with its proprietary Spiegelmer® technology. Its lead products are NOX-E36, NOX-A12 and NOX-H94, targeting diabetic complications, oncology and hematology. These Spiegelmer® compounds act as inhibitors of their respective molecular targets. The company plans ongoing clinical and pre-clinical development of these lead programs. To support that work, NOXXON completed a financing in 2010. The funds will be applied to advance the listed clinical and preclinical programs.

• Nanda Technologies

  Participated · Equity · May 2010

  Nanda Technologies develops a high-throughput full-wafer inspection system used in semiconductor manufacturing, based on a proprietary optical design and image-processing software. Its technology increases inspection speed while maintaining high sensitivity, enabling inspection of every wafer in the process flow rather than sampling. The approach materially lowers inspection cost per wafer compared with existing tools. The company is based in Unterschleissheim, Germany. Nanda will use the recent financing to support pre-production evaluations at leading semiconductor manufacturers. Capital-E will take an active board role to support the company’s further growth.

No current team members are available.